Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Europe Psychedelic Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical | Published Report | Jun 2022 | Europe | 350 Pages | No of Tables: 155 | No of Figures: 52

Report Description

Europe Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Industry Trends and Forecast to 2029

Get Exclusive Sample Copy of this Report Here

Europe Psychedelic Drugs Market Analysis and Insights

Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Get Exclusive Sample Copy of this Report Here

Get Exclusive Sample Copy of this Report Here

The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.

These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Europe psychedelic drugs market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.7% in the forecast period of 2022 to 2029 and is expected to reach USD 607.39 million by 2029 from USD 235.71 million in 2021.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019-2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Countries Covered

U.K., Germany, Italy, France, Spain, Russia, Poland, Netherland, Hungary, Austria, Norway, Switzerland, Ireland, Belgium, Lithuania and Rest of Europe

Market Players Covered

The major companies which are dealing in the market are Jazz Pharmaceuticals, Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Hikma Pharmaceuticals PLC, COMPASS, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd, Avadel, Celon Pharma SA., Cybin Corp., GH Research, Entheon Biomedical Corp, among others

Market Definition

Psychedelic drugs involve various types of chemical substances including lysergic acid diethylamide (LSD) and chemical extracted from plants. These drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

The psychedelic drugs can be categorized into empathogens and dissociative drugs (such as phenylcyclohexyl piperidine (PCP)) and serotonergic (classic hallucinogens) such as LSD. Both types of psychedelic drugs can cause hallucinations and feeling of sensation, moreover, dissociative drugs can make a person to fell out of control from their body or environment and makes them feel disconnected. Based on the source, psychedelic drugs have been categorized under natural and synthetic types.

These drugs have wide applications in the treatment of major depressive disorder, post-traumatic stress disorder, panic disorder, treatment-resistant depression and opiate addiction among others. Psychedelic drugs are also known by several other names such as lysergic acid derivative (LSD) which are also known as blotter, dots, sugar, acid, trips and window pane, ketamine are also known as vitamin K, bump, green, K/special K, purple and super acid, PCP are also known as angel/angel dust, boat/love boat, peace, killer weed, super grass and ozone.

Psychedelic Drugs Market Dynamics

Drivers

  • Growing Acceptance Of Psychedelic Drugs For Treating Depression

Psychedelics have achieved a large popularity within the last decade as are familiarly involved with human mental healing and treatment practices and have the power of mind-healing. The growing researchers and scientist are exploring psychedelic drugs therapeutic value and compounds which could be a new treatment option for people with depression. Continuous research and development in the psychedelic drugs has increased the acceptance of psychedelics medication. Psychedelic drugs promising outcomes have increased the usage of psychedelic drugs across the U.K. and other regions which leads to increasing demand for psychedelic drugs, hence these factors are expected to act as drivers for the growth of the market.

  • Increasing Prevalence Of Depression And Mental Disorders

Mental disorders (or mental illnesses) affects persons feeling, mood, thinking, and behaviour and can be long-lasting (chronic) or occasional. Depression and mental disorders have the ability to affect individual’s capacity by virtue of which they perform their everyday tasks. There are numerous dissimilar types of mental disorders. Depression and mental disorders have increased globally due to various factors including family history and genes, abuse or stress, biological factors, usage of alcohol or recreational drugs and many others.

Additionally, increasing consumption of illicit substances have increased depression and mental disorders. Thus, increasing prevalence of depression and mental disorders are increasing the demand for psychedelic drugs which is expected to act as drivers for the growth of the market.

Get Exclusive Sample Copy of this Report Here

Opportunity

  • Increasing R&D Activities In Psychedelic Drugs

Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. New psychedelic drugs development research has initiated by Albert Hofmann in 1938. He has synthesized the first lysergic acid diethylamide (LSD-25) and now recognized as the first person to ingest LSD after five years later. Hofmann was unaware of the significant effects and actions posed by that product. After a growing period of cultural and scientific exploration in the 1950s and 60s, psychedelic drug development research was slackened to a near halt. Increasing research and development expenditure in the psychedelic drugs is creating new opportunities in the market. Thus, increasing R&D activities in psychedelic drugs is acting as an opportunity for the growth of the market.

Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the psychedelic drugs market in the forecast period of 2022-2029.

Restraint/Challenge

  • High Cost Of Psychedelic Drugs

However, the high cost associated with psychedelic drugs will impede the growth rate of psychedelic drugs market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This psychedelic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more information on psychedelic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on psychedelic drugs market

The COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. Hence, the use of various treatment drugs has widely increased in the world’s population. Hence, the pandemic has effected positively on this market.

Recent Development

  • In August 2020, Janssen Pharmaceuticals, Inc. received approval for its Spravato nasal spray indicated for treatment of suicidal people. As approximately 11% to 12% of Americans suffers from major depressive disorder that led them to commit suicide, this approval provided these patients with a remarkable therapy and paved the way for the company to generate more revenue.

Europe Psychedelic Drugs Market Scope

Europe psychedelic drugs market is segmented into source, type, drugs, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Source

  • Synthetic
  • Natural

On the basis of source, the Europe psychedelic drugs market is segmented into synthetic and natural.

Type

  • Empathogens
  • Dissociatives
  • Others

On the basis of type, the Europe psychedelic drugs market is segmented into empathogens, dissociatives, and others.

Drugs

  • Gamma-Hydroxybutyric Acid
  • Ketamine
  • Psilocybin
  • Others

On the basis of drugs, the Europe psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others.

..Application

  • Narcolepsy,
  • Treatment Resistant Depression
  • Major Depressive Disorder
  • Opiate Addiction
  • Post-Traumatic Stress Disorder
  • Others

On the basis of application, the Europe psychedelic drugs market is segmented into narcolepsy, treatment resistant depression, major depressive disorder, opiate addiction, post-traumatic stress disorder and others.

Route of Administration

  • Oral
  • Inhalation
  • Injectable

On the basis of route of administration, the Europe psychedelic drugs market is segmented into oral, inhalation, injectable.

End User

  • Hospital
  • Specialty Clinics
  • Homecare
  • Others

On the basis of end user, the Europe psychedelic drugs market is segmented into hospital, specialty clinics, homecare, and others.

Distribution Channel

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Get Exclusive Sample Copy of this Report Here

On the basis of distribution channel, the Europe psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy.

Psychedelic Drugs Market Regional Analysis/Insights            

The psychedelic drugs market is analysed and market size insights and trends are provided by country, source, type, drugs, application, route of administration, end user and distribution channel as referenced above.

The countries covered in the psychedelic drugs report are U.K., Germany, Italy, France, Spain, Russia, Poland, Netherland, Hungary, Austria, Norway, Switzerland, Ireland, Belgium, Lithuania and Rest of Europe.

Germany is the country from Europe region dominates the psychedelic drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to high awareness about mental disorders in the region and rapid research development is boosting the market.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Psychedelic Market Share Analysis

The psychedelic drugs market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on psychedelic drugs market.

Some of the major players operating in the psychedelic drugs market are Jazz Pharmaceuticals, Inc., Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.), Hikma Pharmaceuticals PLC, COMPASS, Verrian, Pfizer Inc., F. Hoffmann-La Roche Ltd, Avadel, Celon Pharma SA., Cybin Corp., GH Research, Entheon Biomedical Corp, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe vs. Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE PSYCHEDELIC DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PIPELINE ANALYSIS

4.2 PESTEL ANALYSIS

4.3 PORTER'S FIVE FORCES MODEL

5 REGULATORY FRAMEWORK: EUROPE PSYCHEDELIC DRUGS MARKET

5.1 REGULATORY SCENARIO IN THE U.S.

5.2 REGULATORY SCENARIO IN THE U.K.

5.3 REGULATORY SCENARIO IN INDIA

5.4 REGULATORY SCENARIO IN UAE

5.5 REGULATORY SCENARIO IN AFRICA

5.6 REGULATORY SCENARIO IN BRAZIL

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION

6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS

6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH

6.1.4 ONGOING CLINICAL TRIALS

6.1.5 RISE IN PRODUCT APPROVALS

6.2 RESTRAINTS

6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS

6.2.2 HIGH COST OF PSYCHEDELIC DRUGS

6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS

6.3 OPPORTUNITIES

6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS

6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY

6.3.3 UPCOMING REHABILITATION CENTERS

6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS

6.4 CHALLENGES

6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS

6.4.2 RISE IN ILLEGAL ALTERNATIVES

6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS

7 COVID-19 IMPACT ON THE EUROPE PSYCHEDELIC DRUGS MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE

8.1 OVERVIEW

8.2 EMPATHOGENS

8.3 DISSOCIATIVES

8.4 OTHERS

9 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE

9.1 OVERVIEW

9.2 SYNTHETIC

9.3 NATURAL

10 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS

10.1 OVERVIEW

10.2 GAMMA-HYDROXYBUTYRIC ACID

10.3 KETAMINE

10.4 PSILOCYBIN

10.5 OTHERS

11 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 NARCOLEPSY

11.3 TREATMENT RESISTANT DEPRESSION

11.4 MAJOR DEPRESSIVE DISORDER

11.5 OPIATE ADDICTION

11.6 POST-TRAUMATIC STRESS DISORDER

11.7 OTHERS

12 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 ORAL

12.3 INHALATION

12.4 INJECTABLE

13 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 SPECIALTY CLINICS

13.4 HOMECARE

13.5 OTHERS

14 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITALS PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

15 EUROPE PSYCHEDELIC DRUGS MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 RUSSIA

15.1.7 POLAND

15.1.8 SWITZERLAND

15.1.9 NETHERLANDS

15.1.10 HUNGARY

15.1.11 AUSTRIA

15.1.12 NORWAY

15.1.13 IRELAND

15.1.14 BELGIUM

15.1.15 LITHUANIA

15.1.16 REST OF EUROPE

16 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 JAZZ PHARMACEUTICALS, INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 F. HOFFMANN- LA ROCHE LTD

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 JANSSEN EUROPE SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

18.4.1 COMPANY SNAPSHOT

18.4.2 COMPANY SHARE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENT

18.5 AVADEL

18.5.1 COMPANY SNAPSHOT

18.5.2 PRODUCT PORTFOLIO

18.5.3 RECENT DEVELOPMENT

18.6 CELON PHARMA SA

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 COMPASS

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 CYBIN CORP.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 ENTHEON BIOMEDICAL CORP

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 GH RESEARCH

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 HIKMA PHARMACEUTICALS PLC

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 NRX PHARMACEUTICALS, INC.

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 PHARMATHER HOLDINGS LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 VERRIAN

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 USONAINSTITUTE.ORG

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 EUROPE PSYCHEDELIC DRUGS MARKET, PIPELINE ANALYSIS

TABLE 2 PSYCHEDELICS RESEARCH STUDIES, IN EUROPE

TABLE 3 MENTAL ILLNESS IN THE U.S. ADULTS, IN 2020

TABLE 4 MENTAL DISORDERS, IN THE U.S. ADULTS, IN 2020

TABLE 5 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS

TABLE 6 THE 1971 UN CONVENTION ON PSYCHOTROPIC SUBSTANCES

TABLE 7 MAGIC MUSHROOMS PRICES FOR RESEARCHERS, IN THE U.S.

TABLE 8 COST OF PSYCHEDELIC DRUGS

TABLE 9 PSYCHEDELIC DRUGS R&D ACTIVITIES

TABLE 10 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 EUROPE EMPATHOGENS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE DISSOCIATIVES IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 15 EUROPE SYNTHETIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE NATURAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 18 EUROPE GAMMA-HYDROXYBUTYRIC ACID IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE KETAMINE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE PSILOCYBIN IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE NARCOLEPSY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE TREATMENT RESISTANT DEPRESSION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE MAJOR DEPRESSIVE DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE OPIATE ADDICTION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 EUROPE POST-TRAUMATIC STRESS DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE ORAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 EUROPE INHALATION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 EUROPE INJECTABLE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 EUROPE HOSPITALS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 EUROPE SPECIALTY CLINICS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 EUROPE HOMECARE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 39 EUROPE HOSPITALS PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE RETAIL PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 EUROPE ONLINE PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 EUROPE PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 43 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 45 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 46 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 48 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 49 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 50 GERMANY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 GERMANY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 52 GERMANY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 53 GERMANY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 54 GERMANY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 55 GERMANY PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 GERMANY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 57 U.K. PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 U.K. PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 59 U.K. PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 60 U.K. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 61 U.K. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 62 U.K. PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 U.K. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 FRANCE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 FRANCE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 66 FRANCE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 67 FRANCE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 68 FRANCE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 69 FRANCE PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 FRANCE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 ITALY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 ITALY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 73 ITALY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 74 ITALY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 ITALY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 ITALY PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 ITALY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 SPAIN PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 SPAIN PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 80 SPAIN PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 81 SPAIN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 SPAIN PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 83 SPAIN PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 SPAIN PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 RUSSIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 RUSSIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 87 RUSSIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 88 RUSSIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 89 RUSSIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 RUSSIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 91 RUSSIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 92 POLAND PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 POLAND PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 94 POLAND PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 95 POLAND PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 96 POLAND PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 97 POLAND PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 98 POLAND PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 99 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 101 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 102 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 103 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 104 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 105 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 106 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 108 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 109 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 110 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 111 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 112 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 113 HUNGARY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 HUNGARY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 115 HUNGARY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 116 HUNGARY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 HUNGARY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 118 HUNGARY PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 119 HUNGARY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 120 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 122 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 123 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 124 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 125 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 126 AUSTRIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 127 NORWAY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 NORWAY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 129 NORWAY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 130 NORWAY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 131 NORWAY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 132 NORWAY PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 133 NORWAY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 134 IRELAND PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 IRELAND PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 136 IRELAND PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 137 IRELAND PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 138 IRELAND PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 139 IRELAND PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 140 IRELAND PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 141 BELGIUM PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 BELGIUM PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 143 BELGIUM PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 144 BELGIUM PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 145 BELGIUM PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 146 BELGIUM PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 147 BELGIUM PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 148 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION)

TABLE 150 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)

TABLE 151 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 152 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 153 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 154 LITHUANIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 155 REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 EUROPE PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PSYCHEDELIC DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID

FIGURE 10 EUROPE PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE EUROPE PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PSYCHEDELIC DRUGS MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PSYCHEDELIC DRUGS MARKET

FIGURE 16 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS

FIGURE 17 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS

FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER

FIGURE 19 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021

FIGURE 20 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 21 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 22 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021

FIGURE 24 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION)

FIGURE 25 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029)

FIGURE 26 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 27 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021

FIGURE 28 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)

FIGURE 29 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029)

FIGURE 30 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 31 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021

FIGURE 32 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 33 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 34 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 35 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 36 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 37 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 38 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 39 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, 2021

FIGURE 40 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 41 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 42 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 44 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 45 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 46 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 EUROPE PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021)

FIGURE 48 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021)

FIGURE 49 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 50 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 51 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029)

FIGURE 52 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 EUROPE PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 2 EUROPE PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION

FIGURE 3 EUROPE PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PSYCHEDELIC DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID

FIGURE 10 EUROPE PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PSYCHEDELIC DRUGS MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE EUROPE PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PSYCHEDELIC DRUGS MARKET IN 2022 & 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PSYCHEDELIC DRUGS MARKET

FIGURE 16 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS

FIGURE 17 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS

FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER

FIGURE 19 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021

FIGURE 20 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 21 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 22 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021

FIGURE 24 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION)

FIGURE 25 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029)

FIGURE 26 EUROPE PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 27 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021

FIGURE 28 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)

FIGURE 29 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029)

FIGURE 30 EUROPE PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE

FIGURE 31 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021

FIGURE 32 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 33 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 34 EUROPE PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 35 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 36 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 37 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 38 EUROPE PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 39 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, 2021

FIGURE 40 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 41 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 42 EUROPE PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 44 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 45 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 46 EUROPE PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 EUROPE PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021)

FIGURE 48 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021)

FIGURE 49 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 50 EUROPE PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 51 EUROPE PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029)

FIGURE 52 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19